Nuevocor Doses First Patient in SUNBEAM-LMNA Phase 1/2 Trial and Receives FDA Fast Track Designation for NVC-001 in LMNA Dilated Cardiomyopathy

Nuevocor said its clinical-stage candidate NVC-001 is designed to target the mechanobiological root cause of LMNA dilated cardiomyopathy and may have disease-modifying potential. The provided article excerpt contains no clinical results, timelines or financial figures to assess the candidate’s impact further.